Can-Fite BioPharma Ltd. (CANF)
Develops oral drugs targeting A3 adenosine receptors for cancer, liver disease, and psoriasis.
$3.16+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-76.1%
The outlook
CANF is trading near its 52-week lows, well below its long-term moving averages. Analyst sentiment is mixed, with an average price target suggesting significant upside from current levels, though overall analyst coverage appears limited. The current data reflects a stock in a weak near-term trend.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range5% of the way from its 52-week low to high
Price targetAvg target +153% vs current price
Market cap
$6.8M
52-wk high
$14.60
52-wk low
$2.56
50-day avg
$3.23
200-day avg
$4.74
Trailing P/E
—